CFM
ANIK icon

Catalyst Funds Management’s Anika Therapeutics ANIK Stock Holding History

Catalyst Funds Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,400
Closed -$137K – 1172
2024
Q1 		$137K Buy
+5,400
New +$131K 0.04% 338

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Funds Management's ANIK Position: Q2 2024 in Review

Catalyst Funds Management sold out of Anika Therapeutics (ANIK) in Q2 2024, closing a stake of 5,400 shares — an estimated $137K sold.

Catalyst Funds Management first reported a position in ANIK in Q1 2024 and held it in 1 quarter. The position peaked at $137K in Q1 2024. 114 funds tracked by Wall St. Rank hold ANIK as of Q2 2024.

  • Catalyst Funds Management reported no remaining Anika Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 5,400 Anika Therapeutics shares in Q2 2024, an estimated $137K.
  • Catalyst Funds Management first reported a position in Anika Therapeutics in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Anika Therapeutics position peaked at $137K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.